News | March 02, 2022
USFDA issues new clinical trial guidelines for cancer treatments
USFDA's industry recommendations and cancer Moonshot aim to improve lives of patients and their families
USFDA's industry recommendations and cancer Moonshot aim to improve lives of patients and their families
Covaxin is a whole-virion inactivated Covid-19 investigational vaccine candidate that uses the same vero cell manufacturing platform that has been used in the production of polio vaccines for decades
More than 2,500 submissions are currently under review in the Food and Drug Administration's (FDA) cell and gene therapy pipeline
Resolv ER may remedy leading causes of blindness in adults
APS03118 is a novel innovative drug developed by APS with global independent intellectual property rights for unlimited cancer types
Go-ahead for pivotal clinical trial which is expected to commence by March
Phase 1/2 trial of E-602 expected to open in Q1 2022 in patients with solid tumours
The global multi-center phase-II clinical trial will be a 36-week, multi-center, randomized, double-blind, placebo-controlled trial, followed by a 36-week open-label extension period
JBI-802 is a novel, oral, potent and selective dual inhibitor of two epigenetic targets of the CoREST complex: LSD1 and HDAC6
Intox is a GLP certified pre-clinical contract research organization with its test facilities in Pune
Subscribe To Our Newsletter & Stay Updated
